Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antihypertensive Agents/therapeutic use , Endothelium, Vascular/physiopathology , Indapamide/therapeutic use , Metabolic Syndrome/drug therapy , Perindopril/therapeutic use , Aged , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Antihypertensive Agents/pharmacology , Drug Combinations , Endothelium, Vascular/drug effects , Female , Humans , Indapamide/pharmacology , Male , Middle Aged , Perindopril/pharmacologySubject(s)
Actihaemyl/therapeutic use , Duodenal Ulcer/drug therapy , Stomach Ulcer/drug therapy , Tissue Extracts/therapeutic use , Adult , Cyclic AMP/blood , Cyclic GMP/blood , Drug Evaluation , Duodenal Ulcer/blood , Female , Gastrins/blood , Humans , Insulin/blood , Male , Middle Aged , Stomach Ulcer/bloodABSTRACT
High diagnostic significance of beta 2-microglobulin determination by radioimmunoassay in the blood and urine of patients with the main types of renal pathology (chronic glomerulonephritis, chronic pyelonephritis, hemorrhagic fever with the renal syndrome, and diabetic nephropathy) was shown. A study of beta 2-microglobulin level permitted accurate determination of the localization of pathology in the nephron and assessment of a degree of its expression as well as the detection of initial renal functional disorders, assessment of therapeutic efficacy and dynamic observation of renal function in patients with renal pathology.
Subject(s)
Kidney Diseases/metabolism , beta 2-Microglobulin/analysis , Chronic Disease , Diabetic Nephropathies/diagnosis , Diabetic Nephropathies/metabolism , Diagnosis, Differential , Female , Glomerulonephritis/diagnosis , Glomerulonephritis/metabolism , Hemorrhagic Fever with Renal Syndrome/diagnosis , Hemorrhagic Fever with Renal Syndrome/metabolism , Humans , Kidney Diseases/diagnosis , Male , Pyelonephritis/diagnosis , Pyelonephritis/metabolism , RadioimmunoassayABSTRACT
The beta2-microglobulin (beta2-MCG) test was done in 115 patients with an insulin dependent type of diabetes mellitus: 30 of them were without renal pathology, 58 had diabetes mellitus with diabetic nephropathy (DN), and 27 had concomitant chronic pyelonephritis. The effect of glucosuria and proteinuria on the beta2-MCG level was revealed. DN development and progress resulted in an increase in the beta2-MCG concentration in the blood that correlated with a decrease in the glomerular filtration. beta2-MCG urinary excretion grew in a clinically manifested DN stage only. Concomitant pyelonephritis in diabetes mellitus patients resulted mostly in a rise of the beta2-MCG level in the urine. Its concentration in the urine during the exacerbation of pyelonephritis exceeded the indices of the control group, on an average, by 467.9%. The beta2-MCG test is a valuable additional criterion in the differential diagnosis of DN in diabetes mellitus patients.
Subject(s)
Diabetic Nephropathies/diagnosis , Pyelonephritis/diagnosis , beta 2-Microglobulin/analysis , Adult , Chronic Disease , Diagnosis, Differential , Female , Humans , Kidney/physiopathology , Kidney Failure, Chronic/diagnosis , Male , Middle AgedABSTRACT
A study was made of the content of low molecular protein B2-microglobulin in the blood and urine of 126 patients with chronic renal diseases and 95 healthy persons. As a result of the study it was shown that B2-microglobulin concentration in the blood grows with age. The maximum level of B2-microglobulin was marked in patients with chronic glomerulonephritis. A high level of the urinary excretion of B2-microglobulin with a moderate rise of its concentration in the blood is typical of patients with chronic pyelonephritis during exacerbation. Indices of the B2-microglobulin test are closely related to renal function. The B2-microglobulin test is of great diagnostic significance as it provides an opportunity to establish the nature of proteinuria, site and expression of renal pathologic processes.
